Newsfeeds - Spark Newswire

3 minute read

Mid-Day Market Update: Barnes & Noble Education Drops Following Q2 Results; Cumberland Pharmaceuticals Shares Jump

Today, 5:57 AM

Midway through trading Tuesday, the Dow traded down 0.88% to 34,827.81 while the NASDAQ fell 0.78% to 15,659.31. The S&P also fell, dropping 0.3832% to 4,616.53.

BNED

1 minute read

FDA
News

Why TG Therapeutics Stock Is Falling Today

By Adam Eckert

Today, 5:57 AM

TG Therapeutics Inc (NASDAQ: TGTX) is trading lower Tuesday after the company reported the U.S.

TGTX

1 minute read

TG Therapeutics Announces FDA Has Notified Co. It Plans To Host Meeting Of The Oncologic Drugs Advisory Committee In Connection To Biologics License Application For ublituximab And UKONIQ Combination

By Bill Haddad

Today, 5:57 AM

TG Therapeutics, Inc. (NASDAQ:TGTX), today announced the U.S. Food and Drug Administration (FDA) has notified the Company that it plans to host a meeting of the Oncologic Drugs Advisory Committee (ODAC) in

TGTX

3 minute read

41 Stocks Moving In Monday’s Mid-Day Session

By Lisa Levin

Today, 5:57 AM

Gainers Casper Sleep Inc. (NYSE: CSPR) shares climbed 87.1% to $6.64 after the company agreed to be acquired by Durational Capital Management. The company also reported Q3 earnings results.

AVPT

9 minute read

Benzinga’s Top Ratings Upgrades, Downgrades For November 15, 2021

By Benzinga Insights

Today, 5:57 AM

AKAM

1 minute read

Goldman Sachs Downgrades TG Therapeutics to Sell, Lowers Price Target to $26

By Benzinga Newsdesk

Today, 5:57 AM

Goldman Sachs analyst Graig Suvannavejh downgrades TG Therapeutics (NASDAQ:TGTX) from Neutral to Sell and lowers the price target from $33 to $26.

TGTX

32 minute read

Earnings Scheduled For November 4, 2021

By Benzinga Insights

Today, 5:57 AM

Companies Reporting Before The Bell • DISH Network (NASDAQ:DISH) is likely to report quarterly earnings at $0.91 per share on revenue of $4.45 billion.

AAOI

1 minute read

FDA
News

TG Therapeutics Submits Biologics License Application To The U.S. FDA For Ublituximab As A Treatment For Patients With Relapsing Forms Of Multiple Sclerosis

By Benzinga Newsdesk

Today, 5:57 AM

TG Therapeutics, Inc. (NASDAQ:TGTX), today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) requesting approval of ublituximab, the

TGTX

2 minute read

TG Therapeutics Highlights Publication Of Results From Integrated Safety Analysis Of UKONIQ In Blood Advances

By Benzinga Newsdesk

Today, 5:57 AM

TG Therapeutics, Inc. (NASDAQ:TGTX) today announced the publication of results from an integrated safety analysis of UKONIQ® (umbralisib), the Company’s inhibitor of PI3k-delta and CK1-epsilon, in patients

TGTX

2 minute read

Movers

12 Health Care Stocks Moving In Wednesday’s After-Market Session

By Benzinga Insights

Today, 5:57 AM

Gainers

AEMD